Inpharma Weekly

, Volume 1649, Issue 1, pp 22–22 | Cite as

UCB receives not-approvable letter from US FDA for lacosamide.

Media release


Marketing Neuropathic Pain Medium Release Lacosamide Marketing Approval 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Copyright information

© Adis International Ltd 2008

Personalised recommendations